Safety and Efficacy Evaluation of Pertuzumab for the Neoadjuvant Treatment with HER2-positive Breast Cancer

Abstract

The NeoSphere trial showed that pertuzumab combined with trastuzumab-based chemotherapy improved pCR rates in HER2-positive breast cancer. We retrospectively evaluated the safety and efficacy of pertuzumab combined with trastuzumab-based chemotherapy for neoadjuvant treatment in 17 patients with HER2-positive breast cancer between November 2015 and July 2019 in our institution. Four patients had operable, 12 patients had locally advanced, and 1 patient had inflammatory breast cancer. Eight patients were hormone-receptor-positive and HER2-positive. Nine patients were hormone-receptor-negative and HER2-positive. Seven patients (41%) underwent breast-conserving surgery. The overall pCR (ypT0/is) rate was 58.8%, and this outcome was almost the same as the TRYPHAENA trial. Our result showed that the regimens with pertuzumab for the neoadjuvant treatment were highly active, with acceptable tolerability.